drugset / Trial / NCT06085729

Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC)

NCT06085729

Phase 1/2 Recruiting 30 enrolled M.D. Anderson Cancer Center
NaSingle-groupOpen-labelTreatment

Summary

To find the best dose of ADI-PEG20 that can be given in combination with carboplatin and cabazitaxel to patients with AVPC.

Timeline

Start
2024-02-29
Primary completion
2027-09-02
Completion
2027-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Pegargiminase Protein / enzyme biologic Other
Background Cabazitaxel Other / unclassified Intravenous
Background Carboplatin Small molecule Intravenous

Indications